{"id":"W4388042564","doi":"10.1136/jitc-2023-sitc2023.0695","title":"695 Efficacy and safety of trastuzumab deruxtecan (T-DXd) with durvalumab in patients with non-small cell lung cancer (HER2 altered NSCLC) who progressed on anti-PD1/PD-L1 therapy (HUDSON)","year":2023,"lang":"en","type":"article","venue":"Regular and Young Investigator Award Abstracts","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Alberta; Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Durvalumab; Medicine; Internal medicine; Clinical endpoint; Oncology; Tremelimumab; Lung cancer; Trastuzumab; non-small cell lung cancer (NSCLC); Adverse effect; Cancer; Immunotherapy; Clinical trial; Nivolumab; Ipilimumab; Breast cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006289584,0.0003385029,0.0008025435,0.000181364,0.0001818544,0.0005712874,0.0002913223,0.0003731569,0.001456483],"category_scores_gemma":[0.0006036645,0.0001928223,0.0006917281,0.000249081,0.0002779,0.0004140956,0.0002436195,0.00116689,0.0003170381],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009933496,"about_ca_system_score_gemma":0.0006810838,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002232753,"about_ca_topic_score_gemma":0.004917251,"domain_scores_codex":[0.999803,0.00008407285,0.00001434767,0.00002904599,0.00002277697,0.00004688386],"domain_scores_gemma":[0.9996915,0.00006052273,0.00006253272,0.00001894286,0.00001761513,0.0001488404],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.6043335,0.02208881,0.0431793,0.0003805397,0.001332339,0.0004726202,0.0003231668,0.004473315,0.062434,0.0002125102,0.003282758,0.2574872],"study_design_scores_gemma":[0.1149551,0.7042704,0.1571097,0.00006457468,0.0009228013,0.0007653218,0.0001512525,0.004048732,0.01193003,0.0002128443,0.005524097,0.00004512555],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9979214,0.0008124931,0.0000642465,0.00008652586,0.00002404527,0.00007127639,0.0002652334,0.0000122092,0.0007425506],"genre_scores_gemma":[0.9977655,0.0004595877,0.0001975803,0.0001519386,0.0000327185,0.00005509111,0.0007180253,0.000006697578,0.0006128133],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002232753,"threshold_uncertainty_score":0.007207334,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01045595203227388,"score_gpt":0.2406354814381965,"score_spread":0.2301795294059226,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}